These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16679256)

  • 1. Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis.
    Baliga RR; Ranganna P; Pitt B; Koelling TM
    J Card Fail; 2006 May; 12(4):250-6. PubMed ID: 16679256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
    Mottram PM; Haluska B; Leano R; Cowley D; Stowasser M; Marwick TH
    Circulation; 2004 Aug; 110(5):558-65. PubMed ID: 15277317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
    Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
    Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.
    Ferreira JP; Girerd N; Medeiros PB; Santos M; Carvalho HC; Bettencourt P; Kénizou D; Butler J; Zannad F; Rossignol P
    Clin Res Cardiol; 2016 Jun; 105(6):489-507. PubMed ID: 26615605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms.
    Vizzardi E; Nodari S; Caretta G; D'Aloia A; Pezzali N; Faden G; Lombardi C; Raddino R; Metra M; Dei Cas L
    Am J Med Sci; 2014 Apr; 347(4):271-6. PubMed ID: 24196866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%.
    Ezekowitz JA; Lee DS; Tu JV; Newman AM; McAlister FA
    Am J Cardiol; 2008 Jul; 102(1):79-83. PubMed ID: 18572040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
    Rossello X; Ariti C; Pocock SJ; Ferreira JP; Girerd N; McMurray JJV; Van Veldhuisen DJ; Pitt B; Zannad F
    Clin Res Cardiol; 2019 May; 108(5):477-486. PubMed ID: 30264282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
    Beygui F; Cayla G; Roule V; Roubille F; Delarche N; Silvain J; Van Belle E; Belle L; Galinier M; Motreff P; Cornillet L; Collet JP; Furber A; Goldstein P; Ecollan P; Legallois D; Lebon A; Rousseau H; Machecourt J; Zannad F; Vicaut E; Montalescot G;
    J Am Coll Cardiol; 2016 Apr; 67(16):1917-27. PubMed ID: 27102506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms.
    Vizzardi E; Sciatti E; Bonadei I; D'Aloia A; Tartière-Kesri L; Tartière JM; Cohen-Solal A; Metra M
    Clin Res Cardiol; 2015 Dec; 104(12):1078-87. PubMed ID: 26058790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone in patients with systolic heart failure and mild symptoms.
    Zannad F; McMurray JJ; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B;
    N Engl J Med; 2011 Jan; 364(1):11-21. PubMed ID: 21073363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Preiss D; van Veldhuisen DJ; Sattar N; Krum H; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
    Eur J Heart Fail; 2012 Aug; 14(8):909-15. PubMed ID: 22611047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.
    Ezekowitz JA; McAlister FA
    Eur Heart J; 2009 Feb; 30(4):469-77. PubMed ID: 19066207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry.
    Oh J; Kang SM; Song MK; Hong N; Youn JC; Han S; Jeon ES; Cho MC; Kim JJ; Yoo BS; Chae SC; Oh BH; Choi DJ; Lee MM; Ryu KH
    Am Heart J; 2015 May; 169(5):713-720.e3. PubMed ID: 25965719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.